florbetaben is an approved drug (EMA & FDA (2014))
Compound class:
Synthetic organic
Comment: Florbetaben F18 is the third PET (positron-emission tomography) reagent approved to identify amyloid-β (Aβ) as a diagnostic biomarker in the brains of patients with Alzheimer's disease (AD) [1]. Flutemetamol and florbetapir are the two other PET reagents approved for Aβ detection. These diagnostic tools allow direct and non-invasive in vivo visualisation and quantification of Aβ.
|
|
Selectivity at ligand targets | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|